BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Lantern Pharma

Lantern Pharma logo

Founded
2013
Patents
9
Clinical Trials
1
Publications
5

Technologies

AI Companies (Drug Discovery)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action. Lantern also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent therapy combinations. Our approach, which leverages our RADR™ platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

cancer drug development genetic screen precision oncology


Posts Mentioning This Company

9 Publicly Traded Biotechs Utilizing AI-based Research Platforms

  
Disclaimer: This post is not investment advice of any kind; it is for informational purposes only. Neither BPT Analytics Ltd nor the authors of this post endorse or recommend any particular stocks or investment opportunities. Consult relevant professional service providers for any investment decisions at all times.    In a report, The Landscape …

A Parade of AI-driven Biotechs Going Public in 2020-2021

  
Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …

Artificial Intelligence Yields Early Results in Drug Discovery

  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …
SHARE